Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Medicinal product and method for treatment of conditions affecting neural stem cells or progenitor cells

a neural stem cell and product technology, applied in the direction of drug compositions, peptide/protein ingredients, metabolic disorders, etc., can solve the problems of neurological and cognitive deficits, damage to the brain, etc., and achieve the effect of modulating the proliferation and/or differentiation of neural stem cells

Inactive Publication Date: 2005-02-10
ERIKSSON PETER
View PDF5 Cites 41 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0008] It has now been found that by using growth hormone, or an analogue thereof, or another substance leading to increased concentrations of growth hormone or analogues thereof, it is possible to modulate the proliferation and / or differentiation of neural stem cells and progenitor cells from the adult CNS. The present invention thus provides new possibilities to treat injuries to or diseases of the central nervous system that predominantly affect oligodendroglia, astroglia or neuronal cells by modification of proliferation cell genesis and / or differentiation of neuronal stem cells or progenitor cells in the central nervous system.
[0009] It has also been found that it is possible to control the propagation in vitro of stem cells, progenitor-cells and other cells, especially cells derived from the central nervous system, with the potential to generate neurons, astrocytes or oligodendrocytes. Such cells may e.g. be used for therapeutic purposes in patients.

Problems solved by technology

Damage to the brain by trauma, asphyxia, toxins, ischemia or infections are frequently causing neurological and cognitive deficits.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicinal product and method for treatment of conditions affecting neural stem cells or progenitor cells
  • Medicinal product and method for treatment of conditions affecting neural stem cells or progenitor cells

Examples

Experimental program
Comparison scheme
Effect test

examples

[0039] In this example, the density of BrdU-positive cells in the dentate gyrus of hypophysectomized (Hx) rats treated according to the invention with growth hormone (GH), cortisol (C), and L-thyroxine (T) was compared to the density of BrdU-positive cells in the dentate gyrus of hypophysectomized rats treated with cortisol (C), and L-thyroxine (T), and to the density of the same cells for an untreated unoperated control group.

[0040] Fisher rats (Harlan Sprague Dawley) which were intact or hypophysectomized at 50 days of age were maintained under standardized conditions of temperature (24-26° C.), humidity (50-60%) and with lights on between 0500 and 1900 h.

[0041] The rats had free access to standard laboratory chow and water. Hormonal treatment started 7-10 days after hypophysectomy. All the hypophysectomized rats were given cortisol phosphate (400 μg / kg / day; Solu-Cortef, Upjohn, Puurs, Belgium) and L-thyroxine (10 μg / kg / day; Sigma, USA) diluted in saline as a daily subcutaneous ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Concentrationaaaaaaaaaa
Login to View More

Abstract

Use of a substance that upon administration will lead to increased concentrations of growth hormone, such as growth hormone, a functionally equivalent analogue thereof or a substance that will increase the release of endogenous growth hormone, for the production of a medicinal product for treatment of abnormal conditions affecting neural stem cells, progenitor cells and / or cells derived from neural stem cells or progenitor cells, especially conditions affecting the oligodendroglia, astroglia, and / or neuronal cells. In vitro and in vivo methods for inducing lineage determination, propagating and / or inducing or maintaining the genesis of neurons, oligodendrocytes, astroglial cells from progenitor cells, stem cells and / or cells derived from said cells by administrating to the cells a substance that increases the concentration of growth hormone. Also a method of reducing the genesis of oligodendrocytes, neurons, astroglial cells from progenitor cells or stem cells, wherein a pharmaceutically effective amount of a substance that will lead to a decreased concentration of growth hormone or a functionally equivalent analogue thereof is administered to said patient.

Description

FIELD OF INVENTION [0001] The present invention relates to use of substances that upon administration to a patient will lead to increased concentrations of growth hormone for the production of medicinal products. [0002] The present invention also relates to a method for treatment of abnormal conditions affecting neural stem cells or progenitor cells. BACKGROUND OF THE INVENTION [0003] The result of traumatic, asfyxial, hypoxic, ischemic, toxic, infectious, degenerative or metabolic insults to the central nervous system (CNS) of man may involve a certain degree of damage in several different cell types. Damage to the brain by trauma, asphyxia, toxins, ischemia or infections are frequently causing neurological and cognitive deficits. Degenerative diseases may cause loss of specific populations of cells. For instance Parkinson's disease is associated by specific loss of dopaminergic neurons in the Substantia nigra, similarly, multiple sclerosis is associated with loss of myelin and oli...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K35/12A61K45/00A61K38/27A61P25/00A61P25/28C12N5/071C12N5/079
CPCA61K35/12C12N2501/305C12N5/0618A61K38/27A61P25/00A61P25/28
Inventor ERIKSSON, PETER
Owner ERIKSSON PETER
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com